Table 2.
Clinical outcomes for the total number of participants (n), interquartile range (IQR), and Bleomycin/Vincristine (B/V)
| Variable | Sample size (n) | Value |
|---|---|---|
| Treatment Cycles | 122 | |
| Cycles received, median (IQR) | 16 (6–17 ) | |
| Received≥ 16 cycles (% ) | 66 (54 ) | |
| Reason treatment not completed (%) | 52 | |
| Died | 23 (44 ) | |
| Defaulted | 24 (46 ) | |
| Moved to another HIV treatment facility | 2 (4) | |
| Toxicity | 2 (4) | |
| Disease Progression | 1 (2) | |
| Treatment stock out (%) | 122 | |
| Had no missed doses due to stock out (B or V) | 62 (51 ) | |
| Had 1 missed dose due to stock out | 13 (11 ) | |
| Had >1 missed dose due to stock out | 47 (39 ) | |
| Drugs missed due to stock out (%) | 122 | |
| Had 1 missed dose of bleomycin | 14 (12 ) | |
| Had >1 missed dose of bleomycin | 22 (18) | |
| Had 1 missed dose of vincristine | 8 (7) | |
| Had >1 missed dose of vincristine | 28 (23) | |
| Adverse events during treatment (%) | 122 | |
| Grade 2 anemia | 14 (12 ) | |
| Grade 3/4 anemia | 4 (3) | |
| Grade 2 neutropenia | 19 (16) | |
| Grade 3/4 neutropenia | 12 (10) | |
| Grade 2 thrombocytopenia | 1 (0.8) | |
| Grade 3/4 thrombocytopenia | 0 (0) | |
| Non-hematologic grade 3/4 event | 0 (0) | |
| Had at least one delayed or reduced dose due to adverse event | 0 (0) | |
| Vital Status (% ) | 122 | |
| Alive | 67 (55 ) | |
| Died | 33 (27) | |
| Lost to Follow-Up | 22 (18) | |
| 48 weeks response (%) | 99 | |
| Complete response | 35 (35 ) | |
| Partial response | 28 (28 ) | |
| Stable disease | 4 (4) | |
| Progressive disease | 32 (32) |